Background {#Sec1}
==========

Delirium is a severe neuropsychiatric syndrome mainly precipitated by acute illness, affecting at least 1 in 8 inpatients in industrialised countries. \[[@CR1]--[@CR3]\] Symptoms include acute onset of inattention, other cognitive deficits, altered level of consciousness, and psychosis. \[[@CR4]\] Delirium has multiple adverse consequences, including higher mortality, longer hospital stay, and increased institutionalisation. \[[@CR5]--[@CR7]\] It is also highly distressing for patients, carers and staff. \[[@CR8]\]

A range of studies have demonstrated that delirium is associated with future long-term cognitive impairment. \[[@CR9]--[@CR15]\] However, these have major methodological limitations, either:(i)Delirium outcomes have been measured without pre-morbid baseline cognitive assessments, i.e. observed cognitive impairment at follow-up is confounded by undiagnosed pre-existing cognitive impairment (Fig. [1](#Fig1){ref-type="fig"}*, top panel*); \[[@CR13], [@CR16]\] or(ii)Delirium has been retrospectively ascertained, so detailed information on the features any delirium is lacking (Fig. [1](#Fig1){ref-type="fig"}*, middle panel*). \[[@CR9]--[@CR12], [@CR14], [@CR15]\]Fig. 1Studies examining delirium in relation to cognitive decline. *Top panel*: Hospitalised cohorts lack prospective measures of pre-morbid cognition. *Middle panel*: Population cohorts characterise cognition in community, retrospectively ascertaining delirium. *Lower panel*: A cohort prospectively tracking cognition before, during and after acute illness

Thus, a critical gap is that no study has involved all three of the essential elements of (a) determining baseline cognitive function, then (b) ascertaining delirium prospectively, and then (c) assessing delirium's impact on future long-term cognitive impairment. This is the key approach of the current study (Fig. [1](#Fig1){ref-type="fig"}*, bottom panel*).

Prospective ascertainment of delirium is important for several reasons. First, it is less subject to recall bias, which is common in the context of residual cognitive impairment. Second, prospective ascertainment allows for detailed assessment of the features of delirium. This is crucial because there are wide variations in the features of delirium, including severity, duration, and aetiology. \[[@CR17]\] Such variations likely influence the risk of long-term cognitive impairment because delirium features affect other outcomes. \[[@CR18]--[@CR21]\] Finally, a focus on delirium would make possible the differentiation between its specific impact on cognitive outcomes, as opposed to the cognitive decline described in association with acute hospitalisation in general. \[[@CR22]--[@CR24]\]

To advance our understanding of the relationship between delirium and long-term cognitive impairment, we need to address the following question: does delirium, and its features (including severity, duration, and presumed aetiologies), predict long-term cognitive impairment, independent of cognitive impairment at baseline?

A definitive understanding of the natural history of delirium on risk of long-term cognitive impairment would have implications for identification and follow-up of patients at high risk of dementia, targeting acute treatment strategies, directing further research on mechanisms, and providing prognostic information to patients and carers.

Methods {#Sec2}
=======

**Aim** To determine the impact of delirium, and its features, on the risk of long-term cognitive impairment in a population sample.

**Objective 1** Recruit a population sample, the Delirium and Population Health Informatics Cohort (DELPHIC) (*n* = 2000).

**Objective 2** Undertake a minimum of two community-based cognitive assessments, at baseline and two years.

**Objective 3** Ascertain cumulative incidence of delirium (across community and hospital settings).

**Objective 4** Quantify impact of delirium on change in long-term cognitive function.**Hypothesis** Incident delirium is associated with changes in global cognitive scores (pre-delirium compared to scores at two-year follow-up).

Design {#Sec3}
======

This is a prospective study of delirium and its features in relation to long-term cognitive impairment, recruiting a population sample and assessing cognition before, during and after delirium. Although DELPHIC is the scientific name for this study, recruitment will be known locally under the name: Long-term Information and Knowledge for Ageing (LINKAGE) Camden ([www.linkage-camden.com](http://www.linkage-camden.com)).

Population setting and sample {#Sec4}
-----------------------------

The sampling frame is geographically defined by the London Borough of Camden. Camden has 230,000 residents, 16,500 (7%) of whom are aged ≥70. It is one of the most socio-economically varied areas of Europe. There is wide ethnic diversity; 16% of the population age ≥ 65 are non-White British according to the 2011 census.

All health care (primary and secondary) is commissioned by a single Clinical Commissioning Group (CCG) comprising 39 GP surgeries. The CCG is also co-terminus with provision of community rehabilitation (district nurses, physiotherapy, occupational therapy) and all community mental health services are provided by Camden and Islington NHS Foundation Trust. Social services and public health are provided by the local authority directly. Camden is served by two acute hospitals, University College Hospital (UCH) and the Royal Free Hospital (RFH). These are the main sites for clinical ascertainment of delirium. Together, this represents the opportunity to determine and integrate the entire health and social care usage of participants over the follow-up period.

Eligibility {#Sec5}
-----------

**Inclusion criteria:** Resident in Camden, registered with a Camden GP, age ≥ 70 years.

**Exclusion criteria:** Severe hearing impairment or aphasia, unable to speak English sufficiently to undertake any cognitive assessment, terminal phase of illness.

Participant characteristics {#Sec6}
---------------------------

Participants are recruited from the 39 general practices in sequence, initially targeting the larger practices and purposively including a wide socio-economic distribution. Two care homes are also involved, with the aim of including a representative proportion of the Camden population in residential and nursing care (approximately 5% of sample). Patients previously under care of University College and Royal Free Hospitals are also approached. Patients known to Camden Memory Service are invited (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Study flow diagram showing recruitment sources, follow-up and expected attrition over two years

Through approaching participants from GP registers (generally healthy), those known to hospital services (enriched for comorbidity) and memory clinics (enriched for dementia) in a 8:1:1 ratio, the target sample is expected to match the age structure of the 2011 census, as well as have the expected distribution of cognitive function in the population using data from the Cognitive Function and Ageing Study II. \[[@CR25]\]

Consent {#Sec7}
-------

Consent is obtained in line with the principles of Good Clinical Practice. At the start of the study, participants will also be asked to consider their wish to remain in the study in the event that they lose capacity during the study period.

This study will involve participants who lack capacity because it is specifically about cognitive impairment and its acute and chronic determinants. At this project's heart is the recognition that older adults with cognitive impairment have high health and social care needs, but with little research that understands the impact of having cognitive impairment as individuals move between primary, secondary and intermediate care. This research is designed to investigate directly the needs of adults with cognitive impairment, including those unable to give consent for themselves. To not include such participants introduces bias into the research and leaves clinicians and policy makers with no research data to improve care for older patients unable to give consent and invalidate the study almost entirely. \[[@CR26]\]

For those lacking capacity, a consultee will be sought. Consultees will be routinely sought for all participants, including those with capacity who give consent for this. Where necessary, this may include the GP acting as a professional consultee in line with Section 32 of the Mental Capacity Act. In many cases, consultees will provide important collateral information and their continued involvement will be encouraged. Capacity can fluctuate during delirium and dementia. Where an event occurs that is part of the study (e.g. hospitalisation), consultees will be sought if the participant is unable to give continued consent as appropriate. Thereby, it is intended that for those individuals who lose capacity at any stage the research will continue to be able to participate under the terms of the Mental Capacity Act 2005.

Data to be collected {#Sec8}
--------------------

All participants undergo a baseline assessment, repeated two years later. Data collection started in March 2017 and end of the follow-up period will be in March 2020. Those admitted to hospital will be seen throughout their admission, usually daily. Participants discharged from hospital, and those deemed to be at high risk for delirium will be contacted every two months by telephone in order to estimate incidence of delirium in the community using the Informant Assessment of Geriatric Delirium \[[@CR27]\] and quantify trajectories of recovery after delirium (Fig. [3](#Fig3){ref-type="fig"}). The data acquired in each setting are summarised in Table [1](#Tab1){ref-type="table"}.Fig. 3Schematic showing telephone contacts and cognitive testing in four examples, depending on baseline risk for delirium. Both the number of contacts and cognitive assessments increase in the event of hospitalisationTable 1Summary of assessmentsBaseline and follow-upHospitalDomainInstrumentDomainInstrumentSociodemographicDelirium severityMDASGeneral healthFrom NSHDArousalOSLACo-morbiditiesInattentionDelAppMedicationsBalance and mobilityHABAMLife Space AssessmentPADLBarthelQuality of lifeEQ5D-5 LFrailtyCFSVision and hearingFrom NSHDLaboratory valuesContinenceICIQ-SFConstipationPainVASLeisure time physical activityNSHDGrip strengthNottingham electronic dynamometerDental healthPodiatric healthFallsFrom CC75CCo-morbiditiesCIRS-GNutritionMNAMedicationsAnti-cholinergic burden scaleDeliriumFrom NSHDAcute physiologyAPACHE-II, NEWSDepressionGDS-4, CES-D8Subjective memory complaintFrom NSHDCognitionTICS-m; verbal fluency; selected parts of ACE-IIIPADLBarthel scoreIADLNEADS*NSHD MRC* National Survey for Health and Development (10.5522/NSHD/Q103); *EQ5D-5 L* EuroQol (5 domain); *ICIQ-SF* International Consultation on Incontinence Questionnaire - Short Form; *CC75C* Cambridge City over-75 s Cohort; *MNA* Mini-Nutritional Assessment; *GDS* Geriatric Depression Scale; *CES-D* Center for Epidemiological Studies -- Depression; *TICS-m* modified Telephone Interview for Cognitive Assessment; *ACE-III* Addenbrooke's Cognitive Examination III; *PADL* Personal Activities of Daily Living; *IADL* Instrumental Activities of Daily Living; *NEADS* Nottingham Extended Activities of Daily living scale; *MDAS* Memorial Delirium Assessment Scale; *OSLA* Observational Scale for Level of Arousal; *HABAM* Hierarchical Assessment of Balance and Mobility; *CFS* Clinical Frailty Scale; *CIRS-G* Cumulative Illness Rating Scale for Geriatrics; Acute Physiology and Chronic Health Evaluation-II; *NEWS* National Early Warning Score

Community assessments {#Sec9}
---------------------

These are mainly undertaken by telephone, though some participants are seen at home or in the Bloomsbury Centre for Clinical Phenotyping. The whole sample is assessed at baseline and two years later (primary outcome measure). In addition, a 12.5% subsample (*n* = 250) of the most cognitively impaired (highest-risk for delirium) is being proactively monitored by the research team (Fig. [3](#Fig3){ref-type="fig"}).

The baseline contact comprises:Consent for involvement in DELPHIC, specifically including: hospital assessments in the event of acute illness (particularly if capacity is impaired through delirium or dementia at subsequent contacts); record linkage of electronic health data in primary and secondary careIf capacity to consent is impaired, a consultee declaration will be sought, in line with NHS Health Research Authority guidanceNomination of consulteesAdministration of the Modified Telephone Interview for Cognitive Status (TICS-m), \[[@CR28], [@CR29]\] plus verbal fluency and other memory tests from the Addenbrooke's Cognitive Examination IIIOther measures of health and wellbeing, including: general health, co-morbidities, medications, health behaviours, hearing, vision, quality of life, continence, falls, depression, personal and instrumental activities of daily living (Table [1](#Tab1){ref-type="table"})

TICS-m is a widely-used, validated test which takes 10 min to administer over the telephone or in person. \[[@CR30]\] Cognitive domains measured include: orientation, concentration, delayed recall, language, praxis, calculation, verbal comprehension. It is scored out of 50 points and has a normal distribution in population samples of older persons. \[[@CR31]\] While severe hearing impairment would preclude assessment with TICS-m, it is possible to test individuals with severe visual and/or motor impairments.

Proactive telephone contact for highest risk {#Sec10}
--------------------------------------------

Age and baseline cognitive impairment are the strongest risk factors for delirium. A subsample of the 12.5% most cognitively impaired (*n* = 250) (Table [2](#Tab2){ref-type="table"}) are selected for enhanced delirium surveillance, before and after any hospitalisations (Fig. [3](#Fig3){ref-type="fig"}). This strategy has previously been used for ascertaining other acute events in population samples, e.g. falls. \[[@CR32], [@CR33]\] This allows for the most complete understanding of how delirium develops and patterns of recovery across healthcare settings, thereby challenging the assumption that most delirium presents to acute hospitals.Table 2Age structure of DELPHIC in relation to dementia prevalence, hospital presentation rate and sample for proactive contactAge (years)CamdenDELPHIC cohort (N)^a^Prevalent dementia N (*%*)Incident dementia N (%/year)Expected mortality (annual)% Proactive contactHigh-risk (N)70--745631676*34%*182.7%50.72%14*5%*3375--794442533*27%*305.7%91.63.5%19*10%*5380--843455414*21%*419.9%143.36.5%27*15%*6285--892048246*12%*3816%124.815%37*20%*49≥901095131*7%*3527%64.815%20*40%*5316,67120001628.14611712.5%250^a^Proportions mapped to Camden population estimates (2011 census). Prevalent and incident dementia cases estimated from CFAS-II data. \[[@CR25], [@CR47]\]

The research team undertake telephone contacts each day (Monday-Friday), covering the subsample of 250 participants and/or their nominated trusted advisors (consultees) every two months (Fig. [3](#Fig3){ref-type="fig"}). Each contact has the following purposes:Assess any new health problem (every two months).Assess any delirium symptoms using the validated Informant Interview for Geriatric Delirium (I-AGeD \[[@CR27]\]). This provides key information on community delirium both before hospitalisation and tracks recovery after hospital (every two months).Repeated TICS-m in participants after discharge (every four months) (Fig. [3](#Fig3){ref-type="fig"}).

Hospital assessments {#Sec11}
--------------------

Admissions lists are screened Monday-Friday, identifying participants who have been admitted (emergency and elective). Specific audit data from Camden practices, along with reports from NHS Digital, indicate that the admission rate in this age group is up to 20/1000/month. This amounts to 1000 events over the two year study period, with the highest-risk being admitted recurrently.

Identified admissions are assessed for delirium. Key definitions are given in Table [3](#Tab3){ref-type="table"}. Data recorded includes information collected through usual clinical care:Demographic: age, sex, education, place of residence, co-resident supportClinical: admission details, physiological measurements (National Early Warning Scores (NEWS)), illness severity scores (Acute Physiology and Chronic Health Evaluation (APACHE) II (minus arterial blood gas)), medications.Delirium: general cognition (TICS-m), MDAS, arousal, attention (including the DelApp \[[@CR34]\]), functional balance and mobility, aetiological factors.Table 3Key definitions**Delirium:** DSM-IV**Duration:** Days in delirium, determined by consensus of all data obtained: direct assessment, informant interview, hospital and community clinical records.**Severity:** Serial Memorial Delirium Assessment Scale (MDAS) scores associated with each delirium episode.**Aetiology:** Principal precipitating causes (infective/inflammatory; pharmacological; metabolic; other), determined by consensus of all data obtained.**Cognitive function:** Modified Telephone Interview for Cognitive Status (TICS-m) score.

Participants admitted to UCH or RFH are seen every weekday. Relevant clinical data from out-of-hours (including weekends and participants discharged before assessment) maximise ascertainment using validated method for detecting delirium from medical notes and interviews with ward staff and family. \[[@CR35]\] Hospitalised participants will be followed up at St Pancras Hospital if they are discharged to bed-based rehabilitation. Participants at St Pancras will be seen a minimum of twice a week.

After hospitalisation, participants (and/or proxies) will continue to be proactively contacted as described above. There will be up to five additional occasions for administering TICS-m, adding longitudinal information on trajectories to recovery or persistent delirium (Fig. [3](#Fig3){ref-type="fig"}).

Delirium ascertainment is supervised by DD, with difficult cases used for ongoing training and knowledge sharing. Complex cases are adjudicated on a monthly basis with input from specialist old age liaison psychiatry (ES). The final delirium variables (incidence, duration, severity, aetiology) will be derived by an expert consensus panel, blinded to outcome data. All available inpatient assessments, telephone contacts, electronic hospital and GP records collected for data linkage will be used.

Additional data sources {#Sec12}
-----------------------

Participants are asked to consent for access to their NHS medical and social care notes, including data from GP, community mental health, community rehabilitation and social services records throughout the duration of the study. The facility to do this comes from the Camden Integrated Digital Record.

Statistical methods {#Sec13}
-------------------

### Power calculations for hypothesis {#Sec14}

Figure [2](#Fig2){ref-type="fig"} shows the expected mortality for hospitalised persons (delirium and non-delirium). \[[@CR5], [@CR9], [@CR23], [@CR36]\] Overall mortality in the population aged ≥70 years is 12%/year (Office for National Statistics). Attrition from causes other than death is estimated as 10%. Calculations used the *sampsi* command in Stata (version 12.1), and assume α = 0.05 and β = 0.9. The most conservative estimate of TICS-m standard deviation reported in the literature (SD = 7.2) was used. \[[@CR31]\]

A clinically significant change in the two-year total TICS-m score would be 6 (out of 50) points for hospitalised delirium patients (change within-person for incident delirium cases) (hypothesis) and 3 points for hospitalised persons without delirium (compared to delirium cases). \[[@CR23], [@CR24]\] This effect size is consistent with other studies using this type of primary outcome where incident delirium was associated with change in global cognition scales of 2.5 (out of 28) points (Blessed Information-Memory-Concentration test) \[[@CR11]\] and 4 (out of 30) points (Mini-Mental State Examination). \[[@CR10]\]

The resulting sample size is *n* = 215 to detect the primary outcome (within-person change in the incident delirium group) and *n* = 431 to compare differences between hospitalised participants without delirium. This allows a margin to assess 70% of admissions or a 50% overestimate of delirium cases, and still be sufficiently powered.

Statistical analyses {#Sec15}
--------------------

**Outcome:** TICS-m score at follow-up.

**Exposures:**

**Main exposure:** delirium (severity (MDAS scores); duration (days), modelled as a time-varying covariate across the whole study period); aetiology (four categories: infective/inflammatory; metabolic; pharmacological; other).

**Confounders:** baseline**:** TICS-m score at baseline, age, sex, ethnicity (three categories), education level (three categories); illness severity**:** APACHE II at admission and daily total NEWS scores.

Analyses {#Sec16}
--------

Delirium incidence will be expressed as an annual rate, and described stratified by age.Linear regression, where outcome is TICS-m score at two years, will be used (hypothesis). 14 parameters are proposed, this can be accommodated by a follow-up sample of 1400.Timing of delirium is important and delirium variables will be analysed as time-varying covariates, where this can be considered 'time at risk' for change in TICS-m score. This also allows the effects of recurrent delirium to be assessed and is flexible for differences in time intervals between delirium occurrences and follow-up.More detailed analyses of trajectories in relation to repeated TICS-m scores will be possible using random-effects models. \[[@CR37]\]Data missing at random will be treated using multiple imputation.Where appropriate, shared parameters models may jointly link random-effects models with survival analyses to account for attrition due to death. \[[@CR38]\]

Patient and public involvement {#Sec17}
------------------------------

Patient and public involvement operates through the formation of a PPI group with input throughout the course of the study. The group is drawn from interested persons in Camden, including those involved with the CCG, Age UK, Carers UK, Alzheimer's Society. The PPI group is involved in refining the study documentation (PIS, consent forms), recruitment strategies as well as dissemination of findings. The group meets every four months, where new study questions and modalities of data collection are considered.

Discussion {#Sec18}
==========

The DELPHIC study represents an opportunity to characterise prospectively the impact of delirium on long-term cognitive impairment. It will provide a definitive estimate of cumulative incidence of delirium across settings in a whole population. Prospectively linking a community sample with hospitalisations will lead to new knowledge on pathways to long-term cognitive impairment, overcoming the limitations of previous studies in selected samples. DELPHIC also offers an opportunity to explore mechanisms by providing a population framework to nest representative samples testing hypotheses from experimental studies. \[[@CR39], [@CR40]\]

With respect to other cohort studies, DELPHIC is closely related to CFAS-DECIDE, where the delirium ascertainment protocols were developed in conjunction. \[[@CR41]\] The community assessments have overlap with measures undertaken in the MRC National Survey for Health and Development. \[[@CR42], [@CR43]\] In ascertaining both delirium and dementia, DELPHIC will be a contributing cohort to the Dementias Platform UK.

DELPHIC will lead to a resource for insights into the delirium-dementia relationship from its biological underpinnings through to the public health implications. A systematic characterisation of temporal patterns of acute illness, hospitalisation, delirium and cognitive outcomes is urgently required. \[[@CR44]\] DELPHIC will also inform how underlying dementia influences the incidence and detection of delirium, by adding empirical data to the clinical uncertainties surrounding delirium superimposed on dementia. \[[@CR45], [@CR46]\] By analysing whole population transitions of cognitive function in older people across healthcare settings, DELPHIC will lead to greater understanding of progression of cognitive impairments in ageing.
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